Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

A Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects With Friedreich's Ataxia

← catalyst calendar

NCT07778836 · readout ≤ 1,074 d

Sponsored by Larimar Therapeutics, Inc. (industry) · LRMR — their whole pipeline →.

Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
150estimated
Sites
3
Country
United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-21

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2026-08-05estimatedWhen the study began enrolling
Primary completionJul 2029estimatedThe date the last participant is measured for the primary outcome — the readout window
Study completionDec 2029estimatedThe whole study's end, after follow-up
First posted2026-08-21actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2026-08-21actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

  • Friedreich Ataxia
  • Friedreich's Ataxia

Interventions

  • Drug: Nomlabofusp — also filed as CTI-1601
  • Drug: Placebo — also filed as CTI-1601 Placebo, Nomlabofusp Placebo

Primary outcomes

what the primary-completion date above is the date OF
Change from baseline in Upright Stability Score (USS) subscale E of modified Friedreich's Ataxia Rating Scale (mFARS) at Week 72 (Region-specific)
measured Baseline, Weeks 12, 24, 36, 48, 72
Change from baseline in the total modified Friedreich's Ataxia Rating Scale (mFARS) at Week 72 (Region-specific)
measured Baseline, Weeks 12, 24, 36, 48, 72

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · LRMR's whole pipeline · Catalyst calendar · Every registered study · What changed